Butterfly Network
Butterfly Network's revenue rose 19.0% to $98 million in fiscal 2025. Its operating margin was −88.5%, up from −90.7% a year earlier. Free cash flow was −$16 million. The diluted share count rose 16.7%.
Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on equity is net income as a share of shareholders' equity. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.
Charts show fiscal years, from the 10-K filings.
What Butterfly Network does
Butterfly Network makes handheld ultrasound devices that fit in a pocket and connect to a phone or tablet app. Its devices are built on a semiconductor chip rather than the traditional ultrasound probe. Doctors, nurses and other healthcare workers use them for point-of-care ultrasound, which means scanning at the patient's side.
It sells the devices and also earns revenue from software subscriptions, cloud-based software for healthcare systems, and education and professional services. It markets to healthcare systems, physicians and other providers, through its own sales force, independent distributors and an online channel, and sells in over 30 countries. Butterfly says it competes with established makers of portable ultrasound, which it views as extensions of cart-based hospital ultrasound.
Butterfly has only a limited history of selling products and has lost money since it began. It buys a key chip component from a single supplier, TSMC, and uses a single contract manufacturer, Benchmark, to assemble its devices.
Its biggest risks, as it describes them
- It has a short history of sales and has lost money since it began.
- Market acceptance of its products and services may be slower than it needs.
- Rapid technology change in medical devices could make its products obsolete.
- It depends on a single chip supplier, TSMC, and a single manufacturer, Benchmark.
- Conflict near Taiwan could disrupt its chip supply.
Income statement
Butterfly Network lost money in fiscal 2025: a net loss of $77 million.
Returns on capital
Balance sheet
Five years at a glance
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | 423 | 238 | — | 89 | 150 |
| Debt incl. finance leases | — | — | — | — | — |
| Net debt (negative means net cash) | — | — | — | — | — |
| Net debt to EBITDA | — | — | — | — | — |
| Debt to equity | — | — | — | — | — |
| Interest coverage | −296.1x | −96,510.0x | — | −59.0x | −58.0x |
| Current ratio | 10.3x | 7.0x | 5.2x | 4.0x | 3.8x |
| Quick ratio | 9.6x | 5.8x | 3.6x | 2.5x | 2.9x |
Cash flow
Projections
Project Butterfly Network's revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.
Insider trades
Over the 12 months between November 14, 2025 and November 13, 2026, 2 insiders bought $13.1 million of Butterfly Network shares on the open market, and 8 insiders sold $125.5 million, $78.1 million of it under trading plans set up in advance.
| Date | Insider | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Nov 11, 2026 | John N. DohertyEVP, CFO | Sold plan | 50,000 | $7.00 | $350,000 | Form 4 |
| Sep 23, 2026 | Joseph DevivoPresident & CEO, Director | Sold plan | 3,169 | $10.02 | $31,753 | Form 4 |
| Sep 22, 2026 | Joseph DevivoPresident & CEO, Director | Sold plan | 2,811 | $10.00 | $28,110 | Form 4 |
| Sep 4, 2026 | Steve CashmanChief Business Officer | Sold | 140,112 | $7.30 | $1.0 million | Form 4 |
| Sep 4, 2026 | Megan CarlsonCAO and SVP, Finance | Sold | 13,804 | $7.30 | $100,769 | Form 4 |
| Sep 2, 2026 | Nicholas CaezzaDeputy General Counsel | Sold | 1,709 | $8.15 | $13,928 | Form 4 |
| Aug 17, 2026 | Larry RobbinsDirector | Sold | 582,500 | $8.97 | $5.2 million | Form 4 |
| Aug 14, 2026 | Larry RobbinsDirector | Sold | 824,700 | $8.70 | $7.2 million | Form 4 |
| Aug 14, 2026 | Phanstiel S. LouiseDirector | Bought | 115,200 | $8.68 | $999,936 | Form 4 |
| Aug 13, 2026 | Larry RobbinsDirector | Sold | 890,533 | $9.24 | $8.2 million | Form 4 |
| Aug 11, 2026 | Nicholas CaezzaDeputy General Counsel | Sold | 10,000 | $9.75 | $97,500 | Form 4 |
| Aug 10, 2026 | Joseph DevivoPresident & CEO, Director | Sold plan | 68,346 | $10.01 | $684,143 | Form 4 |
Indicators
Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.
| Indicator | FY23 | FY24 | FY25 |
|---|---|---|---|
| Piotroski F-score | — | — | — |
| Rule of 40 | −168.9% | −29.6% | 2.5% |
| Altman Z'' | −4.26 | −6.43 | −5.51 |
| Accruals ratio | −9.7% | −11.0% | −23.3% |
The nine F-score tests
| Test | FY23 | FY24 | FY25 |
|---|---|---|---|
| Net income is positive | Fail | Fail | Fail |
| Cash from operations is positive | Fail | Fail | Fail |
| Return on assets rose | Fail | Pass | Fail |
| Cash from operations exceeds net income | Pass | Pass | Pass |
| Debt fell relative to assets | — | — | — |
| Current ratio rose | Fail | Fail | Fail |
| Share count didn't rise | Fail | Fail | Fail |
| Gross margin rose | Fail | Pass | Fail |
| Revenue rose relative to assets | Pass | Pass | Pass |
| F-score | — | — | — |
Compare
Put Butterfly Network side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.
Similar companies
| Company | Year | Revenue growth | Operating margin | Free cash flow margin | Return on capital | Net debt to EBITDA | F-score | Compare |
|---|---|---|---|---|---|---|---|---|
| Butterfly Network | FY25 | 19.0% | −88.5% | −16.4% | — | — | — | |
| Kestra Medical Technologies | FY26 | 59.0% | −141.6% | −122.6% | — | — | 4 | Compare |
| Beta Bionics | FY25 | 53.9% | −71.5% | −56.1% | — | — | — | Compare |
| Ceribell | FY25 | 36.1% | −65.6% | −46.7% | — | — | — | Compare |
| Delcath Systems | FY25 | 129.1% | 0.8% | 24.6% | 2.8% | −101.4x | 6 | Compare |
7 years of figures
| Fiscal year | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|
| Income statement | |||||||
| Revenue | 28 | 46 | 63 | 73 | 66 | 82 | 98 |
| Revenue growth | — | 67.7% | 35.3% | 17.3% | −10.2% | 24.5% | 19.0% |
| Gross profit | −21 | −61 | 17 | 40 | 17 | 49 | 46 |
| Research and development | 49 | 50 | 74 | 88 | 56 | 38 | 36 |
| Operating income | −102 | −162 | −193 | −193 | −146 | −74 | −86 |
| Net income | −100 | −163 | −32 | −169 | −134 | −72 | −77 |
| Diluted EPS (US$) | −17.08 | −26.87 | −0.19 | −0.84 | −0.65 | −0.34 | −0.31 |
| Diluted shares (millions) | 6 | 6 | 174 | 200 | 205 | 212 | 247 |
| Cash flow | |||||||
| Cash from operations | −120 | −82 | −189 | −169 | −99 | −42 | −13 |
| Capital expenditure | 4 | 2 | 8 | 18 | 6 | 3 | 3 |
| Free cash flow | −125 | −84 | −197 | −187 | −105 | −44 | −16 |
| Dividends paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share buybacks | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Stock-based compensation | 6 | 11 | 48 | 42 | 28 | 21 | 23 |
| Balance sheet at fiscal year end | |||||||
| Cash and short-term investments | 90 | 60 | 423 | 238 | — | 89 | 150 |
| Debt incl. finance leases | — | — | — | — | — | — | — |
| Total assets | — | 147 | 572 | 418 | 304 | 256 | 296 |
| Total liabilities | — | 148 | 124 | 92 | 84 | 87 | 101 |
| Shareholders' equity | −212 | −362 | 448 | 325 | 220 | 169 | 196 |
| Margins and ratios | |||||||
| Gross margin | −75.8% | −132.4% | 27.3% | 53.8% | 25.6% | 59.5% | 46.9% |
| Operating margin | −370.9% | −349.4% | −308.0% | −263.0% | −221.0% | −90.7% | −88.5% |
| Net margin | −361.4% | −351.9% | −51.8% | −229.9% | −202.9% | −88.3% | −79.0% |
| Free cash flow margin | −452.8% | −181.8% | −315.0% | −255.4% | −158.7% | −54.1% | −16.4% |
| Rule of 40 (growth + FCF margin) | — | −114.1% | −279.7% | −238.1% | −168.9% | −29.6% | 2.5% |
| Return on capital | — | — | — | — | — | — | — |
| Return on equity | — | — | −75.6% | −43.6% | −49.0% | −37.3% | −42.2% |
| Return on assets | — | — | −9.0% | −34.1% | −37.0% | −25.9% | −27.9% |
| Net debt to EBITDA | — | — | — | — | — | — | — |